申请人:Yissum Research Development Company of the Hebrew University of Jerusalem
公开号:US20040242684A1
公开(公告)日:2004-12-02
The present invention concerns compounds and their use to inhibit the activity of a receptor tyrosine kinase. The invention is preferably used to treat cell proliferative disorders such as cancers charcterized by over-activity or inappropriate activity HER2 or EGFR.
本发明涉及化合物及其用途,用于抑制受体酪氨酸激酶的活性。该发明最好用于治疗细胞增殖性疾病,如由HER2或EGFR过度活跃或不适当活跃引起的癌症。